{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:17:32Z","timestamp":1790623052624,"version":"4.1.0"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1038\/s41401-019-0304-y","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T15:08:28Z","timestamp":1570201708000},"page":"483-498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein"],"prefix":"10.1038","volume":"41","author":[{"given":"Ming-ming","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Rudrawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D","family":"Mellick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,4]]},"reference":[{"key":"304_CR1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J. Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368\u201376.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"304_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","volume":"5","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management. Lancet Neurol. 2006;5:235\u201345.","journal-title":"Lancet Neurol"},{"key":"304_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nrd3430","volume":"10","author":"WG Meissner","year":"2011","unstructured":"Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P. et al. Priorities in Parkinson\u2019s disease research. Nat Rev Drug Discov. 2011;10:377\u201393.","journal-title":"Nat Rev Drug Discov"},{"key":"304_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2013;14:38\u201348.","journal-title":"Nat Rev Neurosci"},{"key":"304_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/ana.410260403","volume":"26","author":"DC German","year":"1989","unstructured":"German DC, Manaye K, Smith WK, Woodward DJ, Saper CB. Midbrain dopaminergic cell loss in Parkinson\u2019s disease: computer visualization. Ann Neurol. 1989;26:507\u201314.","journal-title":"Ann Neurol"},{"key":"304_CR6","first-page":"920","volume":"3","author":"F Lewy","year":"1912","unstructured":"Lewy F. Paralysis agitans. I. Pathologische anatomie. Handb der neurologie. 1912;3:920\u201358.","journal-title":"Handb der neurologie"},{"key":"304_CR7","unstructured":"Tr\u00e9tiakoff C. Contribution \u00e0 l'\u00e9tude de l'anatomie pathologique du locus niger de Soemmering avec quelques d\u00e9ductions relatives \u00e0 la pathog\u00e9nie des troubles du tonus musculaire et de la maladie de Parkinson. Universit\u00e9 de Paris, Paris; 1919."},{"key":"304_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"304_CR9","doi-asserted-by":"crossref","unstructured":"Gelb DJ, Oliver E, Gilman S. Diagnostic Criteria for Parkinson Disease. Arch Neurol. 1999;56:33\u20139.","DOI":"10.1001\/archneur.56.1.33"},{"key":"304_CR10","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30:1591\u2013601.","journal-title":"Mov Disord"},{"key":"304_CR11","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1212\/WNL.57.8.1497","volume":"57","author":"AJ Hughes","year":"2001","unstructured":"Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson\u2019s disease. Neurology. 2001;57:1497\u20139.","journal-title":"Neurology"},{"key":"304_CR12","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","volume":"86","author":"G Rizzo","year":"2016","unstructured":"Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;86:566\u201376.","journal-title":"Neurology"},{"key":"304_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/archneur.1994.00540150027011","volume":"51","author":"GV Sawle","year":"1994","unstructured":"Sawle GV, Playford ED, Burn DJ, Cunningham VJ, Brooks DJ. Separating Parkinson\u2019s disease from normality: discriminant function analysis of fluorodopa F 18 positron emission tomography data. Arch Neurol. 1994;51:237\u201343.","journal-title":"Arch Neurol"},{"key":"304_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.neulet.2013.02.012","volume":"541","author":"C Ohtsuka","year":"2013","unstructured":"Ohtsuka C, Sasaki M, Konno K, Koide M, Kato K, Takahashi J, et al. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson\u2019s disease using neuromelanin-sensitive MR imaging. Neurosci Lett. 2013;541:93\u20138.","journal-title":"Neurosci Lett"},{"key":"304_CR15","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/nrneurol.2014.205","volume":"10","author":"M Politis","year":"2014","unstructured":"Politis M. Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat Rev Neurol. 2014;10:708\u201322.","journal-title":"Nat Rev Neurol"},{"key":"304_CR16","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1002\/mds.22242","volume":"23","author":"CH Hawkes","year":"2008","unstructured":"Hawkes CH. The prodromal phase of sporadic Parkinson\u2019s disease: does it exist and if so how long is it? Mov Disord. 2008;23:1799\u2013807.","journal-title":"Mov Disord"},{"key":"304_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2009.08.007","volume":"16","author":"CH Hawkes","year":"2010","unstructured":"Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson\u2019s disease. Parkinsonism Relat Disord. 2010;16:79\u201384.","journal-title":"Parkinsonism Relat Disord"},{"key":"304_CR18","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1212\/01.wnl.0000312279.49272.9f","volume":"70","author":"H Braak","year":"2008","unstructured":"Braak H, Del Tredici K. Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology. 2008;70:1916\u201325.","journal-title":"Neurology"},{"key":"304_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00401-008-0355-5","volume":"115","author":"K Del Tredici","year":"2008","unstructured":"Del Tredici K, Braak H. A not entirely benign procedure: progression of Parkinson\u2019s disease. Acta Neuropathol. 2008;115:379\u201384.","journal-title":"Acta Neuropathol"},{"key":"304_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, R\u00fcb U, De Vos RA, Steur ENJ, Braak E. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol Aging. 2003;24:197\u2013211.","journal-title":"Neurobiol Aging"},{"key":"304_CR21","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.1016\/S1353-8020(08)70017-8","volume":"13","author":"MB Youdim","year":"2007","unstructured":"Youdim MB, Geldenhuys WJ, Van der Schyf CJ. Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson\u2019s disease? Parkinsonism Relat Disord. 2007;13:S281\u2013S91.","journal-title":"Parkinsonism Relat Disord"},{"key":"304_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/B978-0-12-386467-3.00006-6","volume":"100","author":"CJ Van der Schyf","year":"2011","unstructured":"Van der Schyf CJ, Geldenhuys WJ. Multimodal drugs and their future for Alzheimer\u2019s and Parkinson\u2019s disease. Int Rev Neurobiol. 2011;100:107\u201325.","journal-title":"Int Rev Neurobiol"},{"key":"304_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1517\/17460441.2015.1041495","volume":"10","author":"CJ Van der Schyf","year":"2015","unstructured":"Van der Schyf CJ. Rational drug discovery design approaches for treating Parkinson\u2019s disease. Expert Opin Drug Discov. 2015;10:713\u201341.","journal-title":"Expert Opin Drug Discov"},{"key":"304_CR24","doi-asserted-by":"publisher","first-page":"11282","DOI":"10.1073\/pnas.90.23.11282","volume":"90","author":"K U\u00e9da","year":"1993","unstructured":"U\u00e9da K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:11282\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"304_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0166-2236(97)01213-7","volume":"21","author":"DF Clayton","year":"1998","unstructured":"Clayton DF, George JM. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 1998;21:249\u201354.","journal-title":"Trends Neurosci"},{"key":"304_CR26","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.febslet.2011.01.009","volume":"585","author":"DP Hong","year":"2011","unstructured":"Hong DP, Xiong W, Chang JY, Jiang C. The role of the C\u2010terminus of human \u03b1\u2010synuclein: intra\u2010disulfide bonds between the C\u2010terminus and other regions stabilize non\u2010fibrillar monomeric isomers. FEBS Lett. 2011;585:561\u20136.","journal-title":"FEBS Lett"},{"key":"304_CR27","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.1074\/jbc.M112.403311","volume":"288","author":"U Dettmer","year":"2013","unstructured":"Dettmer U, Newman AJ, Luth ES, Bartels T, Selkoe D. In vivo cross-linking reveals principally oligomeric forms of \u03b1-synuclein and \u03b2-synuclein in neurons and non-neural cells. J Biol Chem. 2013;288:6371\u201385.","journal-title":"J Biol Chem"},{"key":"304_CR28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1021\/bi501188a","volume":"54","author":"ES Luth","year":"2014","unstructured":"Luth ES, Bartels T, Dettmer U, Kim NC, Selkoe DJ. Purification of \u03b1-synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity. Biochemistry. 2014;54:279\u201392.","journal-title":"Biochemistry"},{"key":"304_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature10324","volume":"477","author":"T Bartels","year":"2011","unstructured":"Bartels T, Choi JG, Selkoe DJ. \u03b1-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011;477:107\u201310.","journal-title":"Nature"},{"key":"304_CR30","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","volume":"14","author":"B Dehay","year":"2015","unstructured":"Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, et al. Targeting \u03b1-synuclein for treatment of Parkinson\u2019s disease: mechanistic and therapeutic considerations. Lancet Neurol. 2015;14:855\u201366.","journal-title":"Lancet Neurol"},{"key":"304_CR31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0896-6273(00)80886-7","volume":"25","author":"A Abeliovich","year":"2000","unstructured":"Abeliovich A, Schmitz Y, Fari\u00f1as I, Choi-Lundberg D, Ho WH, Castillo PE, et al. Mice lacking \u03b1-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000;25:239\u201352.","journal-title":"Neuron"},{"key":"304_CR32","doi-asserted-by":"publisher","first-page":"8797","DOI":"10.1523\/JNEUROSCI.22-20-08797.2002","volume":"22","author":"DE Cabin","year":"2002","unstructured":"Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking \u03b1-synuclein. J Neurosci. 2002;22:8797\u2013807.","journal-title":"J Neurosci"},{"key":"304_CR33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/0896-6273(95)90302-X","volume":"14","author":"A Iwai","year":"1995","unstructured":"Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, De Silva HR, et al. The precursor protein of non-A\u03b2 component of Alzheimer\u2019s disease amyloid is a presynaptic protein of the central nervous system. Neuron. 1995;14:467\u201375.","journal-title":"Neuron"},{"key":"304_CR34","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0165-3806(96)00210-6","volume":"99","author":"GS Withers","year":"1997","unstructured":"Withers GS, George JM, Banker GA, Clayton DF. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res Dev Brain Res. 1997;99:87\u201394.","journal-title":"Brain Res Dev Brain Res"},{"key":"304_CR35","doi-asserted-by":"publisher","first-page":"6365","DOI":"10.1523\/JNEUROSCI.20-17-06365.2000","volume":"20","author":"PJ Kahle","year":"2000","unstructured":"Kahle PJ, Neumann M, Ozmen L, M\u00fcller V, Jacobsen H, Schindzielorz A, et al. Subcellular localization of wild-type and Parkinson\u2019s disease-associated mutant \u03b1-synuclein in human and transgenic mouse brain. J Neurosci. 2000;20:6365\u201373.","journal-title":"J Neurosci"},{"key":"304_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.brainres.2008.08.067","volume":"1244","author":"L Zhang","year":"2008","unstructured":"Zhang L, Zhang C, Zhu Y, Cai Q, Chan P, U\u00e9da K, et al. Semi-quantitative analysis of \u03b1-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody. Brain Res. 2008;1244:40\u201352.","journal-title":"Brain Res"},{"key":"304_CR37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.55782\/ane-2008-1717","volume":"68","author":"SJ Lee","year":"2008","unstructured":"Lee SJ, Jeon H, Kandror KV. Alpha-synuclein is localized in a subpopulation of rat brain synaptic vesicles. Acta Neurobiol Exp (Wars). 2008;68:509\u201315.","journal-title":"Acta Neurobiol Exp (Wars)"},{"key":"304_CR38","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1126\/science.1195227","volume":"329","author":"J Burr\u00e9","year":"2010","unstructured":"Burr\u00e9 J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, S\u00fcdhof TC. \u03b1-Synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329:1663\u20137.","journal-title":"Science"},{"key":"304_CR39","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1523\/JNEUROSCI.5634-10.2011","volume":"31","author":"H Jin","year":"2011","unstructured":"Jin H, Kanthasamy A, Ghosh A, Yang Y, Anantharam V, Kanthasamy AG. \u03b1-Synuclein negatively regulates protein kinase C\u03b4 expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity. J Neurosci. 2011;31:2035\u201351.","journal-title":"J Neurosci"},{"key":"304_CR40","doi-asserted-by":"publisher","first-page":"8135","DOI":"10.1021\/bi052584t","volume":"45","author":"M Zhu","year":"2006","unstructured":"Zhu M, Qin ZJ, Hu D, Munishkina LA, Fink AL. \u03b1-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles. Biochemistry. 2006;45:8135\u201342.","journal-title":"Biochemistry"},{"key":"304_CR41","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1242\/jcs.02481","volume":"118","author":"XM Peng","year":"2005","unstructured":"Peng XM, Tehranian R, Dietrich P, Stefanis L, Perez RG. \u03b1-Synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci. 2005;118:3523\u201330.","journal-title":"J Cell Sci"},{"key":"304_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.neuint.2013.06.010","volume":"63","author":"W Yang","year":"2013","unstructured":"Yang W, Wang X, Duan C, Lu L, Yang H. Alpha-synuclein overexpression increases phospho-protein phosphatase 2A levels via formation of calmodulin\/Src complex. Neurochem Int. 2013;63:180\u201394.","journal-title":"Neurochem Int"},{"key":"304_CR43","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease. Science. 1997;276:2045\u20137.","journal-title":"Science"},{"key":"304_CR44","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/ng0298-106","volume":"18","author":"R Kr\u00fcger","year":"1998","unstructured":"Kr\u00fcger R, Kuhn W, M\u00fcller T, Woitalla D, Graeber M, K\u00f6sel S, et al. AlaSOPro mutation in the gene encoding \u03b1-synuclein in Parkinson\u2019s disease. Nat Genet. 1998;18:106\u20138.","journal-title":"Nat Genet"},{"key":"304_CR45","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/ana.10795","volume":"55","author":"JJ Zarranz","year":"2004","unstructured":"Zarranz JJ, Alegre J, G\u00f3mez\u2010Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of \u03b1\u2010synuclein causes parkinson and Lewy body dementia. Ann Neurol. 2004;55:164\u201373.","journal-title":"Ann Neurol"},{"key":"304_CR46","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/mds.25421","volume":"28","author":"S Appel\u2010Cresswell","year":"2013","unstructured":"Appel\u2010Cresswell S, Vilarino\u2010Guell C, Encarnacion M, Sherman H, Yu I, Shah B, et al. Alpha\u2010synuclein p. H50Q, a novel pathogenic mutation for Parkinson\u2019s disease. Mov Disord. 2013;28:811\u20133.","journal-title":"Mov Disord"},{"key":"304_CR47","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/ana.23894","volume":"73","author":"S Lesage","year":"2013","unstructured":"Lesage S, Anheim M, Letournel F, Bousset L, Honor\u00e9 A, Rozas N, et al. G51D \u03b1\u2010synuclein mutation causes a novel Parkinsonian\u2013pyramidal syndrome. Ann Neurol. 2013;73:459\u201371.","journal-title":"Ann Neurol"},{"key":"304_CR48","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1212\/WNL.0b013e31828727ba","volume":"80","author":"C Proukakis","year":"2013","unstructured":"Proukakis C, Dudzik CG, Brier T, MacKay DS, Cooper JM, Millhauser GL, et al. A novel \u03b1-synuclein missense mutation in Parkinson disease. Neurology. 2013;80:1062\u20134.","journal-title":"Neurology"},{"key":"304_CR49","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1090278","volume":"302","author":"A Singleton","year":"2003","unstructured":"Singleton A, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. Synuclein locus triplication causes Parkinson\u2019s disease. Science. 2003;302:841.","journal-title":"Science"},{"key":"304_CR50","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","volume":"364","author":"MC Chartier-Harlin","year":"2004","unstructured":"Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. \u03b1-synuclein locus duplication as a cause of familial Parkinson\u2019s disease. Lancet. 2004;364:1167\u20139.","journal-title":"Lancet"},{"key":"304_CR51","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neulet.2004.10.078","volume":"375","author":"GD Mellick","year":"2005","unstructured":"Mellick GD, Maraganore DM, Silburn PA. Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson\u2019s disease. Neurosci Lett. 2005;375:112\u20136.","journal-title":"Neurosci Lett"},{"key":"304_CR52","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jama.296.6.661","volume":"296","author":"DM Maraganore","year":"2006","unstructured":"Maraganore DM, De Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Kr\u00fcger R, et al. Collaborative analysis of \u03b1-synuclein gene promoter variability and Parkinson disease. J Am Med Assoc. 2006;296:661\u201370.","journal-title":"J Am Med Assoc"},{"key":"304_CR53","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/ng.3955","volume":"49","author":"D Chang","year":"2017","unstructured":"Chang D, Nalls MA, Hallgr\u00edmsd\u00f3ttir IB, Hunkapiller J, van der Brug M, Cai F, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson\u2019s disease risk loci. Nat Genet. 2017;49:1511\u20136.","journal-title":"Nat Genet"},{"key":"304_CR54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0070-2153(04)60002-0","volume":"60","author":"EH Norris","year":"2004","unstructured":"Norris EH, Giasson BI, Lee VM. \u03b1-Synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol. 2004;60:17\u201354.","journal-title":"Curr Top Dev Biol"},{"key":"304_CR55","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.bbapap.2010.04.001","volume":"1804","author":"M Biancalana","year":"2010","unstructured":"Biancalana M, Koide S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta Proteins Proteom. 2010;1804:1405\u201312.","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"304_CR56","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/sj.emboj.7600211","volume":"23","author":"CO Fernandez","year":"2004","unstructured":"Fernandez CO, Hoyer W, Zweckstetter M, Jares\u2010Erijman EA, Subramaniam V, Griesinger C, et al. NMR of \u03b1\u2010synuclein\u2013polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J. 2004;23:2039\u201346.","journal-title":"EMBO J"},{"key":"304_CR57","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1074\/jbc.M208249200","volume":"278","author":"T Antony","year":"2003","unstructured":"Antony T, Hoyer W, Cherny D, Heim G, Jovin TM, Subramaniam V. Cellular polyamines promote the aggregation of \u03b1-synuclein. J Biol Chem. 2003;278:3235\u201340.","journal-title":"J Biol Chem"},{"key":"304_CR58","doi-asserted-by":"publisher","first-page":"19509","DOI":"10.1074\/jbc.274.28.19509","volume":"274","author":"SJ Wood","year":"1999","unstructured":"Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL. \u03b1-Synuclein fibrillogenesis Is nucleation-dependent Implications for the pathogenesis of Parkinson\u2032 s disease. J Biol Chem. 1999;274:19509\u201312.","journal-title":"J Biol Chem"},{"key":"304_CR59","doi-asserted-by":"publisher","first-page":"9220","DOI":"10.1523\/JNEUROSCI.2617-07.2007","volume":"27","author":"KM Danzer","year":"2007","unstructured":"Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, et al. Different species of \u03b1-synuclein oligomers induce calcium influx and seeding. J Neurosci. 2007;27:9220\u201332.","journal-title":"J Neurosci"},{"key":"304_CR60","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1038\/emboj.2009.257","volume":"28","author":"DP Karpinar","year":"2009","unstructured":"Karpinar DP, Balija MBG, K\u00fcgler S, Opazo F, Rezaei\u2010Ghaleh N, Wender N, et al. Pre\u2010fibrillar \u03b1\u2010synuclein variants with impaired \u03b2\u2010structure increase neurotoxicity in Parkinson\u2019s disease models. EMBO J. 2009;28:3256\u201368.","journal-title":"EMBO J"},{"key":"304_CR61","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1073\/pnas.1100976108","volume":"108","author":"B Winner","year":"2011","unstructured":"Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, et al. In vivo demonstration that \u03b1-synuclein oligomers are toxic. Proc Natl Acad Sci USA. 2011;108:4194\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"304_CR62","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cell.2012.03.037","volume":"149","author":"N Cremades","year":"2012","unstructured":"Cremades N, Cohen SI, Deas E, Abramov AY, Chen AY, Orte A, et al. Direct observation of the interconversion of normal and toxic forms of \u03b1-synuclein. Cell. 2012;149:1048\u201359.","journal-title":"Cell"},{"key":"304_CR63","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1073\/pnas.1218424110","volume":"110","author":"BK Choi","year":"2013","unstructured":"Choi BK, Choi MG, Kim JY, Yang Y, Lai Y, Kweon DH, et al. Large \u03b1-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc Natl Acad Sci USA. 2013;110:4087\u201392.","journal-title":"Proc Natl Acad Sci USA"},{"key":"304_CR64","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1474-4422(04)00827-0","volume":"3","author":"CW Olanow","year":"2004","unstructured":"Olanow CW, Perl DP, DeMartino GN, McNaught KSP. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol. 2004;3:496\u2013503.","journal-title":"Lancet Neurol"},{"key":"304_CR65","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1074\/jbc.M310994200","volume":"279","author":"M Tanaka","year":"2004","unstructured":"Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM. Aggresomes formed by \u03b1-synuclein and synphilin-1 are cytoprotective. J Biol Chem. 2004;279:4625\u201331.","journal-title":"J Biol Chem"},{"key":"304_CR66","doi-asserted-by":"publisher","first-page":"38173","DOI":"10.1074\/jbc.M110.127753","volume":"285","author":"M-P Hinault","year":"2010","unstructured":"Hinault M-P, Cuendet AFH, Mattoo RU, Mensi M, Dietler G, Lashuel HA, et al. Stable \u03b1-synuclein oligomers strongly inhibit chaperone activity of the Hsp70 system by weak interactions with J-domain co-chaperones. J Biol Chem. 2010;285:38173\u201382.","journal-title":"J Biol Chem"},{"key":"304_CR67","doi-asserted-by":"publisher","first-page":"12924","DOI":"10.1074\/jbc.M306390200","volume":"279","author":"E Lindersson","year":"2004","unstructured":"Lindersson E, Beedholm R, H\u00f8jrup P, Moos T, Gai W, Hendil KB, et al. Proteasomal inhibition by \u03b1-synuclein filaments and oligomers. J Biol Chem. 2004;279:12924\u201334.","journal-title":"J Biol Chem"},{"key":"304_CR68","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1523\/JNEUROSCI.5367-11.2012","volume":"32","author":"E Colla","year":"2012","unstructured":"Colla E, Coune P, Liu Y, Pletnikova O, Troncoso JC, Iwatsubo T, et al. Endoplasmic reticulum stress is important for the manifestations of \u03b1-synucleinopathy in vivo. J Neurosci. 2012;32:3306\u201320.","journal-title":"J Neurosci"},{"key":"304_CR69","doi-asserted-by":"publisher","first-page":"8083","DOI":"10.1523\/JNEUROSCI.1091-10.2010","volume":"30","author":"DA Scott","year":"2010","unstructured":"Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S. A pathologic cascade leading to synaptic dysfunction in \u03b1-synuclein-induced neurodegeneration. J Neurosci. 2010;30:8083\u201395.","journal-title":"J Neurosci"},{"key":"304_CR70","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0002-9440(10)64553-1","volume":"157","author":"LJ Hsu","year":"2000","unstructured":"Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, et al. \u03b1-Synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol. 2000;157:401\u201310.","journal-title":"Am J Pathol"},{"key":"304_CR71","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1385\/JMN:24:3:343","volume":"24","author":"M Hashimoto","year":"2004","unstructured":"Hashimoto M, Kawahara K, Bar-On P, Rockenstein E, Crews L, Masliah E. The role of \u03b1-synuclein assembly and metabolism in the pathogenesis of Lewy body disease. J Mol Neurosci. 2004;24:343\u201352.","journal-title":"J Mol Neurosci"},{"key":"304_CR72","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3233\/JAD-2004-6412","volume":"6","author":"MA Alim","year":"2004","unstructured":"Alim MA, Ma QL, Takeda K, Aizawa T, Matsubara M, Nakamura M, et al. Demonstration of a role for \u03b1-synuclein as a functional microtubule-associated protein. J Alzheimers Dis. 2004;6:435\u201342.","journal-title":"J Alzheimers Dis"},{"key":"304_CR73","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1471-4159.2011.07254.x","volume":"117","author":"S H\u00fcls","year":"2011","unstructured":"H\u00fcls S, H\u00f6gen T, Vassallo N, Danzer KM, Hengerer B, Giese A, et al. AMPA\u2010receptor\u2010mediated excitatory synaptic transmission is enhanced by iron\u2010induced \u03b1\u2010synuclein oligomers. J Neurochem. 2011;117:868\u201378.","journal-title":"J Neurochem"},{"key":"304_CR74","doi-asserted-by":"publisher","first-page":"11750","DOI":"10.1523\/JNEUROSCI.0234-12.2012","volume":"32","author":"MJ Di\u00f3genes","year":"2012","unstructured":"Di\u00f3genes MJ, Dias RB, Rombo DM, Miranda HV, Maiolino F, Guerreiro P, et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci. 2012;32:11750\u201362.","journal-title":"J Neurosci"},{"key":"304_CR75","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1471-4159.2009.06324.x","volume":"111","author":"KM Danzer","year":"2009","unstructured":"Danzer KM, Krebs SK, Wolff M, Birk G, Hengerer B. Seeding induced by \u03b1\u2010synuclein oligomers provides evidence for spreading of \u03b1\u2010synuclein pathology. J Neurochem. 2009;111:192\u2013203.","journal-title":"J Neurochem"},{"key":"304_CR76","doi-asserted-by":"publisher","first-page":"9262","DOI":"10.1074\/jbc.M109.081125","volume":"285","author":"HJ Lee","year":"2010","unstructured":"Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, et al. Direct transfer of \u03b1-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem. 2010;285:9262\u201372.","journal-title":"J Biol Chem"},{"key":"304_CR77","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nrn3887","volume":"16","author":"J Brettschneider","year":"2015","unstructured":"Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ. Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nat Rev Neurosci. 2015;16:109\u201320.","journal-title":"Nat Rev Neurosci"},{"key":"304_CR78","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3233\/JPD-130247","volume":"3","author":"JL Eberling","year":"2013","unstructured":"Eberling JL, Dave KD, Frasier MA. \u03b1-Synuclein imaging: a critical need for Parkinson\u2019s disease research. J Parkinsons Dis. 2013;3:565\u20137.","journal-title":"J Parkinsons Dis"},{"key":"304_CR79","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(14)61010-2","volume":"384","author":"AH Schapira","year":"2014","unstructured":"Schapira AH, Olanow CW, Greenamyre JT, Bezard E. Slowing of neurodegeneration in Parkinson\u2019s disease and Huntington\u2019s disease: future therapeutic perspectives. Lancet. 2014;384:545\u201355.","journal-title":"Lancet"},{"key":"304_CR80","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/09298673113209990216","volume":"21","author":"M Cui","year":"2014","unstructured":"Cui M. Past and recent progress of molecular imaging probes for \u03b2-amyloid plaques in the brain. Curr Med Chem. 2014;21:82\u2013112.","journal-title":"Curr Med Chem"},{"key":"304_CR81","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1111\/j.1471-4159.2008.05245.x","volume":"105","author":"L Ye","year":"2008","unstructured":"Ye L, Velasco A, Fraser G, Beach TG, Sue L, Osredkar T, et al. In vitro high affinity \u03b1\u2010synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem. 2008;105:1428\u201337.","journal-title":"J Neurochem"},{"key":"304_CR82","doi-asserted-by":"publisher","first-page":"10365","DOI":"10.1523\/JNEUROSCI.0630-07.2007","volume":"27","author":"MT Fodero-Tavoletti","year":"2007","unstructured":"Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci. 2007;27:10365\u201371.","journal-title":"J Neurosci"},{"key":"304_CR83","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejphar.2009.06.042","volume":"617","author":"MT Fodero-Tavoletti","year":"2009","unstructured":"Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, et al. In vitro characterisation of BF227 binding to alpha-synuclein\/Lewy bodies. Eur J Pharmacol. 2009;617:54\u20138.","journal-title":"Eur J Pharm"},{"key":"304_CR84","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2174\/1567205011666141107154201","volume":"11","author":"E Levigoureux","year":"2014","unstructured":"Levigoureux E, Lancelot S, Bouillot C, Chauveau F, Verdurand M, Verchere J, et al. Binding of the PET radiotracer [18F] BF227 does not reflect the presence of alpha-synuclein aggregates in transgenic mice. Curr Alzheimer Res. 2014;11:955\u201360.","journal-title":"Curr Alzheimer Res"},{"key":"304_CR85","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1016\/j.bmc.2012.06.023","volume":"20","author":"L Yu","year":"2012","unstructured":"Yu L, Cui J, Padakanti PK, Engel L, Bagchi DP, Kotzbauer PT, et al. Synthesis and in vitro evaluation of alpha-synuclein ligands. Bioorg Med Chem. 2012;20:4625\u201334.","journal-title":"Bioorg Med Chem"},{"key":"304_CR86","doi-asserted-by":"publisher","first-page":"e55031","DOI":"10.1371\/journal.pone.0055031","volume":"8","author":"DP Bagchi","year":"2013","unstructured":"Bagchi DP, Yu L, Perlmutter JS, Xu J, Mach RH, Tu Z, et al. Binding of the radioligand SIL23 to alpha-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS One. 2013;8:e55031.","journal-title":"PLoS One"},{"key":"304_CR87","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/app4010066","volume":"4","author":"X Zhang","year":"2014","unstructured":"Zhang X, Jin H, Padakanti PK, Li J, Yang H, Fan J, et al. Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging alpha-Synuclein. Appl Sci. 2014;4:66\u201378.","journal-title":"Appl Sci"},{"key":"304_CR88","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1021\/acs.jmedchem.5b00571","volume":"58","author":"W Chu","year":"2015","unstructured":"Chu W, Zhou D, Gaba V, Liu J, Li S, Peng X, et al. Design, synthesis, and characterization of 3-(benzylidene)indolin-2-one derivatives as ligands for alpha-synuclein fibrils. J Med Chem. 2015;58:6002\u201317.","journal-title":"J Med Chem"},{"key":"304_CR89","doi-asserted-by":"publisher","first-page":"44305","DOI":"10.1039\/C6RA02710E","volume":"6","author":"M Ono","year":"2016","unstructured":"Ono M, Doi Y, Watanabe H, Ihara M, Ozaki A, Saji H. Structure activity relationships of radioiodinated diphenyl derivatives. RSC Adv. 2016;6:44305\u201312.","journal-title":"RSC Adv"},{"key":"304_CR90","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1016\/j.bmc.2017.10.010","volume":"25","author":"H Watanabe","year":"2017","unstructured":"Watanabe H, Ariyoshi T, Ozaki A, Ihara M, Ono M, Saji H. Synthesis and biological evaluation of novel radioiodinated benzimidazole derivatives for imaging alpha-synuclein aggregates. Bioorg Med Chem. 2017;25:6398\u2013403.","journal-title":"Bioorg Med Chem"},{"key":"304_CR91","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/jlcr.2989","volume":"56","author":"NS Mason","year":"2013","unstructured":"Mason NS, Mathis CA, Klunk WE. Positron emission tomography radioligands for in vivo imaging of A\u03b2 plaques. J Label Comp Radiopharm. 2013;56:89\u201395.","journal-title":"J Label Comp Radiopharm"},{"key":"304_CR92","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-014-0500-6","volume":"14","author":"N Okamura","year":"2014","unstructured":"Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y. Tau PET imaging in Alzheimer\u2019s disease. Curr Neurol Neurosci Rep. 2014;14:500.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"304_CR93","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s40336-016-0217-4","volume":"5","author":"PT Kotzbauer","year":"2016","unstructured":"Kotzbauer PT, Tu Z, Mach RH. Current status of the development of PET radiotracers for imaging alpha synuclein aggregates in Lewy bodies and Lewy neurites. Clin Transl Imaging. 2016;5:3\u201314.","journal-title":"Clin Transl Imaging"},{"key":"304_CR94","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/aps.2015.155","volume":"37","author":"M Xu","year":"2016","unstructured":"Xu M, Ren W, Tang X, Hu Y, Zhang H. Advances in development of fluorescent probes for detecting amyloid-\u03b2 aggregates. Acta Pharmacol Sin. 2016;37:719\u201330.","journal-title":"Acta Pharm Sin"},{"key":"304_CR95","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1529\/biophysj.107.125211","volume":"94","author":"MS Celej","year":"2008","unstructured":"Celej MS, Jares-Erijman EA, Jovin TM. Fluorescent N-arylaminonaphthalene sulfonate probes for amyloid aggregation of alpha-synuclein. Biophys J. 2008;94:4867\u201379.","journal-title":"Biophys J"},{"key":"304_CR96","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.bmc.2007.10.051","volume":"16","author":"KD Volkova","year":"2008","unstructured":"Volkova KD, Kovalska VB, Balanda AO, Losytskyy MY, Golub AG, Vermeij RJ, et al. Specific fluorescent detection of fibrillar alpha-synuclein using mono- and trimethine cyanine dyes. Bioorg Med Chem. 2008;16:1452\u20139.","journal-title":"Bioorg Med Chem"},{"key":"304_CR97","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1042\/BJ20081572","volume":"418","author":"JH Lee","year":"2009","unstructured":"Lee JH, Lee IH, Choe YJ, Kang S, Kim HY, Gai WP, et al. Real-time analysis of amyloid fibril formation of alpha-synuclein using a fibrillation-state-specific fluorescent probe of JC-1. Biochem J. 2009;418:311\u201323.","journal-title":"Biochem J"},{"key":"304_CR98","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1039\/c0an00829j","volume":"136","author":"PK Makwana","year":"2011","unstructured":"Makwana PK, Jethva PN, Roy I. Coumarin 6 and 1,6-diphenyl-1,3,5-hexatriene (DPH) as fluorescent probes to monitor protein aggregation. Analyst. 2011;136:2161\u20137.","journal-title":"Analyst"},{"key":"304_CR99","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s10895-012-1081-x","volume":"22","author":"VB Kovalska","year":"2012","unstructured":"Kovalska VB, Losytskyy MY, Tolmachev OI, Slominskii YL, Segers-Nolten GM, Subramaniam V, et al. Tri- and pentamethine cyanine dyes for fluorescent detection of alpha-synuclein oligomeric aggregates. J Fluoresc. 2012;22:1441\u20138.","journal-title":"J Fluoresc"},{"key":"304_CR100","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1039\/C4CC07911F","volume":"51","author":"CWT Leung","year":"2015","unstructured":"Leung CW, Leung CW,\u00a0Guo F,\u00a0Hong Y,\u00a0Zhao E,\u00a0Kwok RT, et al. Detection of oligomers and fibrils of \u03b1-synuclein by AIEgen with strong fluorescence. Chem Commun. 2015;51:1866\u20139.","journal-title":"Chem Commun"},{"key":"304_CR101","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1016\/j.bbagen.2015.05.021","volume":"1850","author":"AA Deeg","year":"2015","unstructured":"Deeg AA, Reiner AM, Schmidt F, Schueder F, Ryazanov S, Ruf VC, et al. Anle138b and related compounds are aggregation specific fluorescence markers and reveal high affinity binding to alpha-synuclein aggregates. Biochim Biophys Acta. 2015;1850:1884\u201390.","journal-title":"Biochim Biophys Acta"},{"key":"304_CR102","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1021\/acschemneuro.6b00450","volume":"8","author":"H Watanabe","year":"2017","unstructured":"Watanabe H, Ono M, Ariyoshi T, Katayanagi R, Saji H. Novel benzothiazole derivatives as fluorescent probes for detection of beta-amyloid and alpha-synuclein aggregates. ACS Chem Neurosci. 2017;8:1656\u201362.","journal-title":"ACS Chem Neurosci"},{"key":"304_CR103","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.chembiol.2004.08.025","volume":"11","author":"J Li","year":"2004","unstructured":"Li J, Zhu M, Rajamani S, Uversky VN, Fink AL. Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem Biol. 2004;11:1513\u201321.","journal-title":"Chem Biol"},{"key":"304_CR104","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.brainres.2006.12.074","volume":"1139","author":"J Xu","year":"2007","unstructured":"Xu J, Wei C, Xu C, Bennett MC, Zhang G, Li F, et al. Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an \u03b1-synuclein multimer. Brain Res. 2007;1139:220\u20135.","journal-title":"Brain Res"},{"key":"304_CR105","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1471-4159.2006.03707.x","volume":"97","author":"K Ono","year":"2006","unstructured":"Ono K, Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem. 2006;97:105\u201315.","journal-title":"J Neurochem"},{"key":"304_CR106","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1111\/j.1742-4658.2005.04792.x","volume":"272","author":"HT Li","year":"2005","unstructured":"Li HT, Lin DH, Luo XY, Zhang F, Ji LN, Du HN, et al. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration. FEBS J. 2005;272:3661\u201372.","journal-title":"FEBS J"},{"key":"304_CR107","doi-asserted-by":"publisher","first-page":"e3394","DOI":"10.1371\/journal.pone.0003394","volume":"3","author":"FE Herrera","year":"2008","unstructured":"Herrera FE, Chesi A, Paleologou KE, Schmid A, Munoz A, Vendruscolo M, et al. Inhibition of \u03b1-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region. PLoS One. 2008;3:e3394.","journal-title":"PLoS One"},{"key":"304_CR108","doi-asserted-by":"publisher","first-page":"e9234","DOI":"10.1371\/journal.pone.0009234","volume":"16","author":"D Latawiec","year":"2010","unstructured":"Latawiec D, Herrera F, Bek A, Losasso V, Cndotti M, Benetti F, et al. Modulation of alpha-synuclein aggregation by dopamine analogs. PLoS One. 2010;16:e9234.","journal-title":"PLoS ONE"},{"key":"304_CR109","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.1021\/bi0600749","volume":"45","author":"M Masuda","year":"2006","unstructured":"Masuda M, Suzuki N, Taniguchi S, Oikawa T, Nonaka T, Iwatsubo T, et al. Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry. 2006;45:6085\u201394.","journal-title":"Biochemistry"},{"key":"304_CR110","doi-asserted-by":"publisher","first-page":"8322","DOI":"10.1021\/bi901285x","volume":"48","author":"C Lendel","year":"2009","unstructured":"Lendel C, Bertoncini CW, Cremades N, Waudby CA, Vendruscolo M, Dobson CM, et al. On the mechanism of nonspecific inhibitors of protein aggregation: dissecting the interactions of alpha-synuclein with Congo red and lacmoid. Biochemistry. 2009;48:8322\u201334.","journal-title":"Biochemistry"},{"key":"304_CR111","doi-asserted-by":"publisher","first-page":"21057","DOI":"10.1073\/pnas.0902603106","volume":"106","author":"GR Lamberto","year":"2009","unstructured":"Lamberto GR, Binolfi A, Orcellet ML, Bertoncini CW, Zweckstetter M, Griesinger C, et al. Structural and mechanistic basis behind the inhibitory interaction of PcTS on alpha-synuclein amyloid fibril formation. Proc Natl Acad Sci USA. 2009;106:21057\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"key":"304_CR112","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1021\/acs.accounts.5b00507","volume":"49","author":"AA Valiente-Gabioud","year":"2016","unstructured":"Valiente-Gabioud AA, Miotto MC, Chesta ME, Lombardo V, Binolfi A, Fern\u00e1ndez CO. Phthalocyanines as molecular scaffolds to block disease-associated protein aggregation. Acc Chem Res. 2016;49:801\u20138.","journal-title":"Acc Chem Res"},{"key":"304_CR113","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.ejmech.2017.10.002","volume":"143","author":"N Ahsan","year":"2018","unstructured":"Ahsan N, Siddique IA, Gupta S, Surolia A. A routinely used protein staining dye acts as an inhibitor of wild type and mutant alpha-synuclein aggregation and modulator of neurotoxicity. Eur J Med Chem. 2018;143:1174\u201384.","journal-title":"Eur J Med Chem"},{"key":"304_CR114","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0014-5793(97)01290-8","volume":"417","author":"D Howlett","year":"1997","unstructured":"Howlett D, Cutler P, Heales S, Camilleri P. Hemin and related porphyrins inhibit \u03b2\u2010amyloid aggregation. FEBS Lett. 1997;417:249\u201351.","journal-title":"FEBS Lett"},{"key":"304_CR115","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbrc.2014.10.062","volume":"454","author":"Y Liu","year":"2014","unstructured":"Liu Y, Carver JA, Ho LH, Elias AK, Musgrave IF, Pukala TL. Hemin as a generic and potent protein misfolding inhibitor. Biochem Biophys Res Commun. 2014;454:295\u2013300.","journal-title":"Biochem Biophys Res Commun"},{"key":"304_CR116","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1255\/ejms.1359","volume":"21","author":"Y Liu","year":"2015","unstructured":"Liu Y, Graetz M, Ho L, Pukala TL. Ion mobility-mass spectrometry-based screening for inhibition of alpha-synuclein aggregation. Eur J Mass Spectrom. 2015;21:255\u201364.","journal-title":"Eur J Mass Spectrom"},{"key":"304_CR117","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nchem.2129","volume":"7","author":"LM Young","year":"2015","unstructured":"Young LM, Saunders JC, Mahood RA, Revill CH, Foster RJ, Tu LH, et al. Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry-mass spectrometry. Nat Chem. 2015;7:73\u201381.","journal-title":"Nat Chem"},{"key":"304_CR118","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00401-007-0332-4","volume":"115","author":"N Pandey","year":"2008","unstructured":"Pandey N, Strider J, Nolan WC, Yan SX, Galvin JE. Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathol. 2008;115:479\u201389.","journal-title":"Acta Neuropathol"},{"key":"304_CR119","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1021\/cn3001203","volume":"4","author":"PK Singh","year":"2013","unstructured":"Singh PK, Kotia V, Ghosh D, Mohite GM, Kumar A, Maji SK. Curcumin modulates alpha-synuclein aggregation and toxicity. ACS Chem Neurosci. 2013;4:393\u2013407.","journal-title":"ACS Chem Neurosci"},{"key":"304_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/srep09862","volume":"5","author":"N Ahsan","year":"2015","unstructured":"Ahsan N, Mishra S, Jain MK, Surolia A, Gupta S. Curcumin pyrazole and its derivative (N-(3-nitrophenylpyrazole) curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of wild type and mutant alpha-synuclein. Sci Rep. 2015;5:9862.","journal-title":"Sci Rep"},{"key":"304_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/srep28511","volume":"6","author":"NN Jha","year":"2016","unstructured":"Jha NN, Ghosh D, Das S, Anoop A, Jacob RS, Singh PK, et al. Effect of curcumin analogs on \u03b1-synuclein aggregation and cytotoxicity. Sci Rep. 2016;6:28511.","journal-title":"Sci Rep"},{"key":"304_CR122","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nsmb.1437","volume":"15","author":"DE Ehrnhoefer","year":"2008","unstructured":"Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol. 2008;15:558\u201366.","journal-title":"Nat Struct Mol Biol"},{"key":"304_CR123","doi-asserted-by":"publisher","first-page":"8468","DOI":"10.1021\/acs.analchem.6b00731","volume":"88","author":"A Konijnenberg","year":"2016","unstructured":"Konijnenberg A, Ranica S, Narkiewicz J, Legname G, Grandori R, Sobott F, et al. Opposite structural effects of epigallocatechin-3-gallate and dopamine binding to alpha-synuclein. Anal Chem. 2016;88:8468\u201375.","journal-title":"Anal Chem"},{"key":"304_CR124","doi-asserted-by":"publisher","first-page":"7710","DOI":"10.1073\/pnas.0910723107","volume":"107","author":"J Bieschke","year":"2010","unstructured":"Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, et al. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA. 2010;107:7710\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"304_CR125","doi-asserted-by":"publisher","first-page":"21299","DOI":"10.1074\/jbc.M114.554667","volume":"289","author":"N Lorenzen","year":"2014","unstructured":"Lorenzen N, Nielsen SB, Yoshimura Y, Vad BS, Andersen CB, Betzer C, et al. How epigallocatechin gallate can inhibit alpha-synuclein oligomer toxicity in vitro. J Biol Chem. 2014;289:21299\u2013310.","journal-title":"J Biol Chem"},{"key":"304_CR126","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.neuroscience.2014.12.003","volume":"286","author":"M Chen","year":"2015","unstructured":"Chen M, Wang T, Yue F, Li X, Wang P, Li Y, et al. Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral \u03b1-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys. Neuroscience. 2015;286:383\u201392.","journal-title":"Neuroscience"},{"key":"304_CR127","doi-asserted-by":"publisher","first-page":"10624","DOI":"10.1021\/bi2012383","volume":"50","author":"G Grelle","year":"2011","unstructured":"Grelle G, Otto A, Lorenz M, Frank RF, Wanker EE, Bieschke J. Black tea theaflavins inhibit formation of toxic amyloid-beta and alpha-synuclein fibrils. Biochemistry. 2011;50:10624\u201336.","journal-title":"Biochemistry"},{"key":"304_CR128","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1016\/j.bmcl.2009.09.074","volume":"20","author":"C Rivi\u00e8re","year":"2010","unstructured":"Rivi\u00e8re C, Papastamoulis Y, Fortin PY, Delchier N, Andriamanarivo S, Waffo-Teguo P, et al. New stilbene dimers against amyloid fibril formation. Bioorg Med Chem Lett. 2010;20:3441\u20133.","journal-title":"Bioorg Med Chem Lett"},{"key":"304_CR129","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/nu8060367","volume":"8","author":"H Temsamani","year":"2016","unstructured":"Temsamani H, Krisa S, Decossas-Mendoza M, Lambert O, Merillon JM, Richard T. Piceatannol and other wine stilbenes: a pool of inhibitors against alpha-synuclein aggregation and cytotoxicity. Nutrients. 2016;8:367.","journal-title":"Nutrients"},{"key":"304_CR130","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.febslet.2011.03.046","volume":"585","author":"M Caruana","year":"2011","unstructured":"Caruana M, Hogen T, Levin J, Hillmer A, Giese A, Vassallo N. Inhibition and disaggregation of alpha-synuclein oligomers by natural polyphenolic compounds. FEBS Lett. 2011;585:1113\u201320.","journal-title":"FEBS Lett"},{"key":"304_CR131","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.jep.2016.10.040","volume":"194","author":"KC Hung","year":"2016","unstructured":"Hung KC, Huang HJ, Wang YT, Lin AM. Baicalein attenuates alpha-synuclein aggregation, inflammasome activation and autophagy in the MPP+-treated nigrostriatal dopaminergic system in vivo. J Ethnopharmacol. 2016;194:522\u20139.","journal-title":"J Ethnopharmacol"},{"key":"304_CR132","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.bbadis.2016.07.008","volume":"1862","author":"Q Hu","year":"2016","unstructured":"Hu Q, Uversky VN, Huang M, Kang H, Xu F, Liu X, et al. Baicalein inhibits alpha-synuclein oligomer formation and prevents progression of alpha-synuclein accumulation in a rotenone mouse model of Parkinson\u2019s disease. Biochim Biophys Acta. 2016;1862:1883\u201390.","journal-title":"Biochim Biophys Acta"},{"key":"304_CR133","doi-asserted-by":"publisher","first-page":"7722","DOI":"10.1021\/acs.jafc.6b03217","volume":"64","author":"R Hornedo-Ortega","year":"2016","unstructured":"Hornedo-Ortega R, Alvarez-Fernandez MA, Cerezo AB, Richard T, Troncoso AM, Garcia-Parrilla MA. Protocatechuic acid: inhibition of fibril formation, destabilization of preformed fibrils of amyloid-beta and alpha-synuclein, and neuroprotection. J Agric Food Chem. 2016;64:7722\u201332.","journal-title":"J Agric Food Chem"},{"key":"304_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26645-5","volume":"8","author":"L Palazzi","year":"2018","unstructured":"Palazzi L, Bruzzone E, Bisello G, Leri M, Stefani M, Bucciantini M, et al. Oleuropein aglycone stabilizes the monomeric alpha-synuclein and favours the growth of non-toxic aggregates. Sci Rep. 2018;8:8337.","journal-title":"Sci Rep"},{"key":"304_CR135","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.fct.2018.06.059","volume":"120","author":"R Hornedo-Ortega","year":"2018","unstructured":"Hornedo-Ortega R, Cerezo AB, Troncoso AM, Garcia-Parrilla MC. Protective effects of hydroxytyrosol against alpha-synuclein toxicity on PC12cells and fibril formation. Food Chem Toxicol. 2018;120:41\u20139.","journal-title":"Food Chem Toxicol"},{"key":"304_CR136","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1093\/jn\/130.5.1200","volume":"130","author":"MR Olthof","year":"2000","unstructured":"Olthof MR, Hollman PC, Vree TB, Katan MB. Bioavailabilities of quercetin-3-glucoside and quercetin-4\u2032-glucoside do not differ in humans. J Nutr. 2000;130:1200\u20133.","journal-title":"J Nutr"},{"key":"304_CR137","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2174\/138161212798919093","volume":"18","author":"BS Gadad","year":"2012","unstructured":"Gadad BS, Subramanya PK, Pullabhatla S, Shantharam IS, Rao KS. Curcumin-glucoside, a novel synthetic derivative of curcumin, inhibits \u03b1-synuclein oligomer formation relevance to Parkinson\u2019s disease. Curr Pharm Des. 2012;18:76\u201384.","journal-title":"Curr Pharm Des"},{"key":"304_CR138","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.nbd.2014.11.007","volume":"74","author":"MT Ardah","year":"2015","unstructured":"Ardah MT, Paleologou KE, Lv G, Menon SA, Abul Khair SB, Lu JH, et al. Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils. Neurobiol Dis. 2015;74:89\u2013101.","journal-title":"Neurobiol Dis"},{"key":"304_CR139","doi-asserted-by":"publisher","first-page":"86640","DOI":"10.1039\/C6RA17770K","volume":"6","author":"M Liao","year":"2016","unstructured":"Liao M, Zhao Y, Huang L, Cheng B, Huang K. Isoliquiritigenin and liquiritin from Glycyrrhiza uralensis inhibit \u03b1-synuclein amyloid formation. RSC Adv. 2016;6:86640.","journal-title":"RSC Adv"},{"key":"304_CR140","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neuint.2012.10.001","volume":"62","author":"FL da Silva","year":"2013","unstructured":"da Silva FL, Coelho Cerqueira E, de Freitas MS, Goncalves DL, Costa LT, Follmer C. Vitamins K interact with N-terminus alpha-synuclein and modulate the protein fibrillization in vitro. Exploring the interaction between quinones and alpha-synuclein. Neurochem Int. 2013;62:103\u201312.","journal-title":"Neurochem Int"},{"key":"304_CR141","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1039\/C5FO00664C","volume":"7","author":"K Ji","year":"2016","unstructured":"Ji K, Zhao Y, Yu T, Wang Z, Gong H, Yang X, et al. Inhibition effects of tanshinone on the aggregation of alpha-synuclein. Food Funct. 2016;7:409\u201316.","journal-title":"Food Funct"},{"key":"304_CR142","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1021\/ml500222g","volume":"5","author":"KV Sashidhara","year":"2014","unstructured":"Sashidhara KV, Modukuri RK, Jadiya P, Rao KB, Sharma T, Haque R, et al. Discovery of 3-Arylcoumarin-tetracyclic tacrine hybrids as multifunctional agents against Parkinson\u2019s disease. ACS Med Chem Lett. 2014;5:1099\u2013103.","journal-title":"ACS Med Chem Lett"},{"key":"304_CR143","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nchembio.1750","volume":"11","author":"C Galvagnion","year":"2015","unstructured":"Galvagnion C, Buell AK, Meisl G, Michaels TC, Vendruscolo M, Knowles TP, et al. Lipid vesicles trigger \u03b1-synuclein aggregation by stimulating primary nucleation. Nat Chem Biol. 2015;11:229\u201334.","journal-title":"Nat Chem Biol"},{"key":"304_CR144","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1126\/science.1152066","volume":"319","author":"T Yeung","year":"2008","unstructured":"Yeung T, Gilbert GE, Shi J, Silvius J, Kapus A, Grinstein S. Membrane phosphatidylserine regulates surface charge and protein localization. Science. 2008;319:210\u20133.","journal-title":"Science"},{"key":"304_CR145","doi-asserted-by":"publisher","first-page":"E1009","DOI":"10.1073\/pnas.1610586114","volume":"114","author":"M Perni","year":"2017","unstructured":"Perni M, Galvagnion C, Maltsev A, Meisl G, Muller MB, Challa PK, et al. A natural product inhibits the initiation of alpha-synuclein aggregation and suppresses its toxicity. Proc Natl Acad Sci USA. 2017;114:E1009\u2013E17.","journal-title":"Proc Natl Acad Sci USA"},{"key":"304_CR146","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1021\/acschembio.8b00466","volume":"13","author":"M Perni","year":"2018","unstructured":"Perni M, Flagmeier P, Limbocker R, Cascella R, Aprile FA, Galvagnion C, et al. Multistep inhibition of alpha-synuclein aggregation and toxicity in vitro and in vivo by trodusquemine. ACS Chem Biol. 2018;13:2308\u201319.","journal-title":"ACS Chem Biol"},{"key":"304_CR147","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1073\/pnas.1620159114","volume":"114","author":"A Pineda","year":"2017","unstructured":"Pineda A, Burr\u00e9 J. Modulating membrane binding of \u03b1-synuclein as a therapeutic strategy. Proc Natl Acad Sci USA. 2017;114:1223\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"304_CR148","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1093\/brain\/aww238","volume":"139","author":"W Wrasidlo","year":"2016","unstructured":"Wrasidlo W, Tsigelny IF, Price DL, Dutta G, Rockenstein E, Schwarz TC. et al. A de novo compound targeting alpha-synuclein improves deficits in models of Parkinson's disease. Brain. 2016;139:3217\u201336.","journal-title":"Brain"},{"key":"304_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34490-9","volume":"8","author":"DL Price","year":"2018","unstructured":"Price DL, Koike MA, Khan A, Wrasidlo W, Rockenstein E, Masliah E, et al. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson\u2019s disease. Sci Rep. 2018;8:16165.","journal-title":"Sci Rep"},{"key":"304_CR150","doi-asserted-by":"publisher","first-page":"5862","DOI":"10.1074\/jbc.M608126200","volume":"282","author":"Z Qin","year":"2007","unstructured":"Qin Z, Hu D, Han S, Reaney SH, Di Monte DA, Fink AL. Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J Biol Chem. 2007;282:5862\u201370.","journal-title":"J Biol Chem"},{"key":"304_CR151","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bbrc.2015.12.043","volume":"469","author":"T Ibrahim","year":"2016","unstructured":"Ibrahim T, McLaurin J. alpha-Synuclein aggregation, seeding and inhibition by scyllo-inositol. Biochem Biophys Res Commun. 2016;469:529\u201334.","journal-title":"Biochem Biophys Res Commun"},{"key":"304_CR152","doi-asserted-by":"publisher","first-page":"110040","DOI":"10.1039\/C6RA21697H","volume":"6","author":"SH Cha","year":"2016","unstructured":"Cha SH, Heo SJ, Jeon YJ, Park SM. Dieckol, an edible seaweed polyphenol, retards rotenone-induced neurotoxicity and \u03b1-synuclein aggregation in human dopaminergic neuronal cells. RSC Adv. 2016;6:110040.","journal-title":"RSC Adv"},{"key":"304_CR153","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.neurobiolaging.2011.10.015","volume":"33","author":"K Ono","year":"2012","unstructured":"Ono K, Mochizuki H, Ikeda T, Nihira T, Takasaki J, Teplow DB, et al. Effect of melatonin on \u03b1-synuclein self-assembly and cytotoxicity. Neurobiol Aging. 2012;33:2172\u201385.","journal-title":"Neurobiol Aging"},{"key":"304_CR154","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jmb.2010.10.027","volume":"405","author":"CA Braga","year":"2011","unstructured":"Braga CA, Follmer C, Palhano FL, Khattar E, Freitas MS, Romao L, et al. The anti-Parkinsonian drug selegiline delays the nucleation phase of alpha-synuclein aggregation leading to the formation of nontoxic species. J Mol Biol. 2011;405:254\u201373.","journal-title":"J Mol Biol"},{"key":"304_CR155","doi-asserted-by":"publisher","first-page":"10481","DOI":"10.1073\/pnas.1804198115","volume":"115","author":"J Pujols","year":"2018","unstructured":"Pujols J, Pena-Diaz S, Lazaro DF, Peccati F, Pinheiro F, Gonzalez D, et al. Small molecule inhibits alpha-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons. Proc Natl Acad Sci USA. 2018;115:10481\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"304_CR156","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3390\/ijms18030478","volume":"18","author":"J Pujols","year":"2017","unstructured":"Pujols J, Pena-Diaz S, Conde-Gimenez M, Pinheiro F, Navarro S, Sancho J, et al. High-throughput screening methodology to identify alpha-synuclein aggregation inhibitors. Int J Mol Sci. 2017;18:478.","journal-title":"Int J Mol Sci"},{"key":"304_CR157","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s13311-012-0105-1","volume":"9","author":"S Prabhudesai","year":"2012","unstructured":"Prabhudesai S, Sinha S, Attar A, Kotagiri A, Fitzmaurice AG, Lakshmanan R, et al. A novel \u201cmolecular tweezer\u201d inhibitor of alpha-synuclein neurotoxicity in vitro and in vivo. Neurotherapeutics. 2012;9:464\u201376.","journal-title":"Neurotherapeutics"},{"key":"304_CR158","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s13311-017-0544-9","volume":"14","author":"F Richter","year":"2017","unstructured":"Richter F, Subramaniam SR, Magen I, Lee P, Hayes J, Attar A, et al. A molecular tweezer ameliorates motor deficits in mice overexpressing alpha-synuclein. Neurotherapeutics 2017;14:1107\u201319.","journal-title":"Neurotherapeutics"},{"key":"304_CR159","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"J Wagner","year":"2013","unstructured":"Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathol. 2013;125:795\u2013813.","journal-title":"Acta Neuropathol"},{"key":"304_CR160","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40478-016-0310-y","volume":"4","author":"L Tatenhorst","year":"2016","unstructured":"Tatenhorst L, Eckermann K, Dambeck V, Fonseca-Ornelas L, Walle H, Lopes da Fonseca T, et al. Fasudil attenuates aggregation of alpha-synuclein in models of Parkinson\u2019s disease. Acta Neuropathol Commun. 2016;4:39.","journal-title":"Acta Neuropathol Commun"},{"key":"304_CR161","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.tibtech.2013.05.004","volume":"31","author":"Z Hamrang","year":"2013","unstructured":"Hamrang Z, Rattray NJ, Pluen A. Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation. Trends Biotechnol. 2013;31:448\u201358.","journal-title":"Trends Biotechnol"},{"key":"304_CR162","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1021\/cn300076x","volume":"3","author":"LP Jameson","year":"2012","unstructured":"Jameson LP, Smith NW, Dzyuba SV. Dye-binding assays for evaluation of the effects of small molecule inhibitors on amyloid (A\u03b2) self-assembly. ACS Chem Neurosci. 2012;3:807\u201319.","journal-title":"ACS Chem Neurosci"},{"key":"304_CR163","doi-asserted-by":"publisher","first-page":"7012","DOI":"10.1021\/ac050556a","volume":"77","author":"X Cheng","year":"2005","unstructured":"Cheng X, van Breemen RB. Mass spectrometry-based screening for inhibitors of \u03b2-amyloid protein aggregation. Anal Chem. 2005;77:7012\u20135.","journal-title":"Anal Chem"},{"key":"304_CR164","doi-asserted-by":"publisher","first-page":"14432","DOI":"10.1021\/ja063197p","volume":"128","author":"Y Xie","year":"2006","unstructured":"Xie Y, Zhang J, Yin S, Loo JA. Top-down ESI-ECD-FT-ICR mass spectrometry localizes noncovalent protein-ligand binding sites. J Am Chem Soc. 2006;128:14432\u20133.","journal-title":"J Am Chem Soc"},{"key":"304_CR165","doi-asserted-by":"publisher","first-page":"10727","DOI":"10.1074\/jbc.M113.524520","volume":"289","author":"S Acharya","year":"2014","unstructured":"Acharya S, Safaie BM, Wongkongkathep P, Ivanova MI, Attar A, Kl\u00e4rner FG, et al. Molecular basis for preventing \u03b1-synuclein aggregation by a molecular tweezer. J Biol Chem. 2014;289:10727\u201337.","journal-title":"J Biol Chem"},{"key":"304_CR166","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1021\/acschemneuro.9b00092","volume":"10","author":"M Xu","year":"2019","unstructured":"Xu M, Loa-Kum-Cheng W, Zhang H, Quinn RJ, Mellick GD. Identification of a new \u03b1-synuclein aggregation inhibitor via mass spectrometry based screening. ACS Chem Neurosci. 2019;10:2683\u201391.","journal-title":"ACS Chem Neurosci"},{"key":"304_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10432","volume":"7","author":"X Ai","year":"2016","unstructured":"Ai X, Ho CJ, Aw J, Attia AB, Mu J, Wang Y, et al. In vivo covalent cross-linking of photon-converted rare-earth nanostructures for tumour localization and theranostics. Nat Commun. 2016;7:10432.","journal-title":"Nat Commun"},{"key":"304_CR168","doi-asserted-by":"publisher","first-page":"11550","DOI":"10.1039\/C4CC03731F","volume":"50","author":"X Zhang","year":"2014","unstructured":"Zhang X, Tian Y, Yuan P, Li Y, Yaseen MA, Grutzendler J, et al. A bifunctional curcumin analogue for two-photon imaging and inhibiting crosslinking of amyloid beta in Alzheimer\u2019s disease. Chem Commun. 2014;50:11550\u20133.","journal-title":"Chem Commun"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0304-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0304-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-019-0304-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T15:36:30Z","timestamp":1721835390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-019-0304-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,4]]},"references-count":168,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["304"],"URL":"https:\/\/doi.org\/10.1038\/s41401-019-0304-y","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,4]]},"assertion":[{"value":"26 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}